http://www.unboundmedicine.com/medline/ebm/research/bortezomibUnbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.en-usUnbound Medicine, Inc.http://www.unboundmedicine.com/medline/ebm/record/19926132/full_citation/Bone_morphogenetic_proteins_and_receptors_are_over_expressed_in_bone_marrow_cells_of_multiple_myeloma_patients_and_support_myeloma_cells_by_inducing_ID_genes_Grčević D, Kušec R, Kovačić N, et al. 
Bone morphogenetic proteins and receptors are over-expressed in bone-marrow cells of multiple myeloma patients and support myeloma cells by inducing ID genes. [JOURNAL ARTICLE]
Leuk Res 2009 Nov 17.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19924414/full_citation/Salvage_treatment_with_upfront_melphalan_100_mg/m_2__and_consolidation_with_novel_drugs_for_fulminant_progression_of_multiple_myeloma_Krejci M, Adam Z, Buchler T, et al. 
Salvage treatment with upfront melphalan 100 mg/m(2) and consolidation with novel drugs for fulminant progression of multiple myeloma. [JOURNAL ARTICLE]
Ann Hematol 2009 Nov 19.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19924145/full_citation/Heat_stress_triggers_apoptosis_by_impairing_NF_kappaB_survival_signaling_in_malignant_B_cells_Belardo G, Piva R, Santoro MG 
Heat stress triggers apoptosis by impairing NF-kappaB survival signaling in malignant B cells. [JOURNAL ARTICLE]
Leukemia 2009 Nov 19.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19922463/full_citation/Bortezomib_restores_stroma_mediated_APO2L/TRAIL_apoptosis_resistance_in_multiple_myeloma_Perez LE, Parquet N, Mead M, et al. 
Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma. [JOURNAL ARTICLE]
Eur J Haematol 2009 Nov 17.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19921192/full_citation/Clinical_efficacy_of_a_bortezomib_cyclophosphamide_thalidomide_and_dexamethasone__Vel_CTD__regimen_in_patients_with_relapsed_or_refractory_multiple_myeloma:_a_phase_II_study_Kim YK, Sohn SK, Lee JH, et al. 
Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study. [JOURNAL ARTICLE]
Ann Hematol 2009 Nov 18.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19919652/full_citation/Phase_2_study_of_two_sequential_three_drug_combinations_containing_bortezomib_cyclophosphamide_and_dexamethasone_followed_by_bortezomib_thalidomide_and_dexamethasone_as_frontline_therapy_for_multiple_myeloma_Bensinger WI, Jagannath S, Vescio R, et al. 
Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma. [JOURNAL ARTICLE]
Br J Haematol 2009 Nov 16.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19919649/full_citation/Fludarabine_Bortezomib_Myocet_and_rituximab_chemotherapy_in_relapsed_and_refractory_mantle_cell_lymphoma_Orciuolo E, Buda G, Pelosini M, et al. 
Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma. [JOURNAL ARTICLE]
Br J Haematol 2009 Nov 16.
Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19918466/full_citation/Extramedullary_relapse_of_IgA_lambda_myeloma_after_recent_bortezomib_therapy:_a_case_report_Waterhouse DF, Moloney GA, Gargoum FS, et al. 
Extramedullary relapse of IgA-lambda myeloma after recent bortezomib therapy: a case report. [Journal Article]
Cases J 2009.:7456.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19917281/full_citation/Bortezomib_induces_autophagic_death_in_proliferating_human_endothelial_cells_Belloni D, Veschini L, Foglieni C, et al. 
Bortezomib induces autophagic death in proliferating human endothelial cells. [JOURNAL ARTICLE]
Exp Cell Res 2009 Nov 13.
Abstract | Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19914061/full_citation/Bortezomib_and_zoledronic_acid_on_angiogenic_and_vasculogenic_activities_of_bone_marrow_macrophages_in_patients_with_multiple_myeloma_Moschetta M, Di Pietro G, Ria R, et al. 
Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. [JOURNAL ARTICLE]
Eur J Cancer 2009 Nov 12.
Abstract | Full Citation